JP2002523437A5 - - Google Patents

Download PDF

Info

Publication number
JP2002523437A5
JP2002523437A5 JP2000567170A JP2000567170A JP2002523437A5 JP 2002523437 A5 JP2002523437 A5 JP 2002523437A5 JP 2000567170 A JP2000567170 A JP 2000567170A JP 2000567170 A JP2000567170 A JP 2000567170A JP 2002523437 A5 JP2002523437 A5 JP 2002523437A5
Authority
JP
Japan
Prior art keywords
infection
patient
treating
lysostaphin
staphylococcal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000567170A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002523437A (ja
Filing date
Publication date
Priority claimed from US09/140,732 external-priority patent/US6028051A/en
Application filed filed Critical
Publication of JP2002523437A publication Critical patent/JP2002523437A/ja
Publication of JP2002523437A5 publication Critical patent/JP2002523437A5/ja
Pending legal-status Critical Current

Links

JP2000567170A 1998-08-27 1999-08-27 ブドウ球菌性疾患の処置方法 Pending JP2002523437A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US09/140,732 US6028051A (en) 1997-07-23 1998-08-27 Method for the treatment of staphylococcal disease
US09/140,732 1998-08-27
PCT/US1999/020396 WO2000012049A2 (en) 1998-08-27 1999-08-27 A method for the treatment of staphylococcal disease

Publications (2)

Publication Number Publication Date
JP2002523437A JP2002523437A (ja) 2002-07-30
JP2002523437A5 true JP2002523437A5 (https=) 2006-10-19

Family

ID=22492556

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000567170A Pending JP2002523437A (ja) 1998-08-27 1999-08-27 ブドウ球菌性疾患の処置方法

Country Status (12)

Country Link
US (1) US6028051A (https=)
EP (1) EP1107722B1 (https=)
JP (1) JP2002523437A (https=)
AR (1) AR023645A1 (https=)
AT (1) ATE493145T1 (https=)
AU (1) AU5811199A (https=)
CA (1) CA2341699A1 (https=)
DE (1) DE69943089D1 (https=)
IL (1) IL141648A0 (https=)
NO (1) NO20010953L (https=)
WO (1) WO2000012049A2 (https=)
ZA (1) ZA995444B (https=)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7091332B1 (en) 1998-06-22 2006-08-15 University Of Vermont Treatment of staphylococcus infections
US6875903B2 (en) * 1998-06-22 2005-04-05 University Of Vermont Treatment of Staphylococcus infections
US6569830B1 (en) 1999-03-05 2003-05-27 Ambi, Inc. Compositions and methods for treatment of staphylococcal infection while suppressing formation of antibiotic-resistant strains
EP1465990B1 (en) * 2001-12-21 2011-07-13 Biosynexus Incorporated Truncated lysostaphin molecule with enhanced staphylolytic activity
US20030211995A1 (en) * 2001-12-21 2003-11-13 Kokai-Kun John Fitzgerald Methods and formulations for eradicating or alleviating staphylococcal nasal colonization using lysostaphin
US6759881B2 (en) * 2002-03-22 2004-07-06 Rambus Inc. System with phase jumping locked loop circuit
US7572439B2 (en) * 2002-03-26 2009-08-11 Biosynexus Incorporated Enzyme disruption of bacterial biofilms
WO2003082926A2 (en) * 2002-03-26 2003-10-09 Biosynexus Incorporated Antimicrobial polymer conjugates
AU2003296937A1 (en) * 2002-12-10 2004-06-30 Biosynexus Incorporated Topical anti-infective formulations
US20100221237A1 (en) * 2003-03-26 2010-09-02 Biosynexus Incorporated Enzyme disruption of bacterial biofilms
US20070190542A1 (en) * 2005-10-03 2007-08-16 Ling Xinsheng S Hybridization assisted nanopore sequencing
US20080095756A1 (en) * 2006-09-05 2008-04-24 Biosynexus Incorporated Compositions Comprising Lysostaphin Variants And Methods Of Using The Same
WO2009114520A2 (en) * 2008-03-10 2009-09-17 Pharmain Corporation Compositions for treatment with metallopeptidases, methods of making and using the same
US20090304673A1 (en) * 2008-06-10 2009-12-10 Bernd Buchberger Method of Treatment of Inflammatory Diseases
WO2015175774A1 (en) 2014-05-14 2015-11-19 Trustees Of Dartmouth College Deimmunized lysostaphin and methods of use
RU2718554C1 (ru) 2017-09-25 2020-04-08 Георгий Георгиевич Чумбуридзе Термостабильная композиция, обладающая антивирусной и антибактериальной активностью и ее использование
CA3120255A1 (en) * 2018-11-19 2020-05-28 Nordmark Ip Gmbh Ancrod for the treatment or prophylaxis of endocarditis

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3067099A (en) * 1955-09-16 1962-12-04 Lilly Co Eli Vancomycin and method for its preparation
US4931390A (en) * 1986-04-16 1990-06-05 Public Health Research Institute Of The City Of New York, Inc. Expression of the cloned lysostaphin gene
US5858962A (en) * 1987-05-11 1999-01-12 Ambi Inc. Composition for treating mastitis and other staphylococcal infections
US4980163A (en) * 1989-03-01 1990-12-25 Public Health Research Institute Of The City Of New York Novel bacteriocin compositions for use as enhanced broad range bactericides and methods of preventing and treating microbial infection
US5342612A (en) * 1991-12-20 1994-08-30 American Cyanamid Company Compositions for the treatment of mammalian diseases

Similar Documents

Publication Publication Date Title
JP2002523437A5 (https=)
CA2389235A1 (en) Controlled release hydrocodone formulations
JP2002528502A5 (https=)
CA2326517A1 (en) New galenic preparations of meloxicam for oral administration
HK19395A (en) Film-coated solid dosage form of anti-migraine drug
CA2580448A1 (en) Use of [d-meala]3-[etval]4-cyclosporin for the treatment of hepatitis c infection and pharmaceutical composition comprising said [d-meala]3-[etval]4-cyclosporin
JP2002524415A5 (https=)
JP2002527401A5 (https=)
JP2001510795A5 (https=)
JP2004537500A5 (https=)
RU95101385A (ru) Продукты, содержащие g-csf и tnf связующие протеина
CA2313270A1 (en) Use of deferiprone in treating and preventing iron-induced cardiac disease
CA2401000A1 (en) Method of treating and diagnosing sleep disordered breathing and means for carrying out the method
WO1999033450A3 (en) Pharmaceutical composition containing sibutramine and orlistat
AR012731A1 (es) Uso de un derivado de taxano para la preparacion de una composicion farmaceutica , uso de un agente mejorador de la biodicponibilidad de dicho derivado forma de dosificacion oral y conjunto afrmaceutico que lo comprende y metodo para formar a un agente activo biodisponible.
JP2002530353A5 (https=)
Mauceri et al. Flucytosine: an effective oral treatment for chromomycosis
JP2002540148A5 (https=)
WO2001012214A3 (en) MYCOPHENOLATE MOFETIL IN ASSOCIATION WITH PEG-IFN-$g(a)
CA2474430A1 (en) A combination of a thrombolytic agent and levosimendan for the treatment of acute myocardial infarction
CA2091134A1 (en) Therapeutic agent for threatened abortion
JP2002535293A5 (https=)
JP2003522121A5 (https=)
KR900007434A (ko) 시스타틴을 유효 성분으로하는 치료제
WO1996030016A3 (en) Low dose ridogrel formulations and their use for the treatment of inflammatory bowel diseases